IP Library Granted Patent US 9,402,834
Granted Patent B2
US 9,402,834 · App. 14/721,011 · Granted Aug 2, 2016

Human therapeutic agents

Inventors: Gene H. Zaid (Sterling, KS); Thomas W. Burgoyne (Sterling, KS)
Assignee: Ions Pharmaceutical S.à r.l.
A61K31/4375A61K31/11A61K31/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,402,834
App. No.
14/721,011
Granted
Aug 2, 2016
Kind
B2
Abstract

Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.

Claims (11)

1. An anti-cancer composition comprising the combination of at least one curcumin component comprising curcumin, at least on harmine component comprising harmine, and at least one isovanillin component comprising wherein to components of the composition are different and said composition exhibits anti-cancer synergy.

2. The composition of claim 1 , said curcumin being synthetically derived or derived from naturally occurring product(s) containing said curcumin which have been treated so that the curcumin is present at a level of at least about 25% by weight in the treated, curcumin-containing naturally occurring product(s), said harmine being synthetically derived or derived from naturally occurring product(s) containing said harmine which have been treated so that the harmine is present at a level of at least about 25% by weight in the treated, harmine-containing naturally occurring product(s), and said isovanillin being synthetically derived or derived from naturally occurring product(s) containing said isovanillin which have been treated so that the iso vanillin is present at a level of at least about 25% by weight in the treated, isovanillin-containing naturally occurring product(s).

3. The composition of claim 1 , wherein said curcumin, said harmine, and said isovanillin are each at least about 50% pure.

4. The composition of claim 1 , said isovanillin being present in an amount greater than the amounts of the harmine and the curcumin.

5. The composition of claim 1 , the ratio of said at least one curcumin component, said at least one harmine component, and said at least one isovanillin component being from about 0.1-5:0.1-5:0.1-25.

6. The composition of claim 1 , wherein the isovanillin Component(s) is/are be present at a level of from about 25-85%, by weight, the harmine component(s) is/are: present at a level of from about 7-50% by weight, and the curcumin component(s) is/are present at a level of from about 5-40% by weight, based upon the total weight of the three components taken as 100% by weight.

7. The composition of claim 1 , said at least one curcumin, component consisting essentially of curcumin, said at least one harmine component consisting essentially of harmine, and said at least one isovanillin component consisting essentially of isovanillin.

8. The composition of claim 1 , said composition exhibiting anti-cancer synergy with lymphoma, ovarian cancer, or breast cancer cells.

9. The composition of claim 1 , said composition exhibiting anti-cancer synergy with lymphoma cancer cells, MO205.

10. The composition of claim 1 , said composition exhibiting anti-cancer synergy with ovarian cancer cells, A1847.

11. The composition of claim 1 , said composition exhibiting anti-cancer synergy with breast cancer cells, du4475.

Assignments (5)
MERGER Recorded Aug 30, 2018
From: IONS PHARMACEUTICAL S.A R.L.
To: ANKH LIFE SCIENCES LIMITED
Reel/Frame 046760/0741 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2016
From: GENZADA PHARMACEUTICALS LLC
To: IONS PHARMACEUTICAL S.À R.L.
Reel/Frame 039018/0259 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVEYANCE PREVIOUSLY RECORDED AT REEL: 036800 FRAME: 0858. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Jun 23, 2016
From: LIFE PLUS, LLC
To: GENZADA PHARMACEUTICALS LLC
Reel/Frame 039140/0179 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2015
From: LIFE PLUS, LLC
To: GENZADA PHARMACEUTICALS LLC
Reel/Frame 036800/0858 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2015
From: ZAID, GENE H.; BURGOYNE, THOMAS W
To: LIFE PLUS, LLC
Reel/Frame 035713/0266 →
Continuity (3)
Provisional Application 62161090 · May 13, 2015
Provisional Application 62066686 · Oct 21, 2014
Related Publication 20160106724A1 · Apr 21, 2016